# BIOCON (BIOCON) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/biocon

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹385
- Change: +1.32%
- As of: 2026-09-18
- 1D return: +1.32%
- 5D return: -1.70%
- 1M return: -6.67%
- Latest complete quarter: fy27_q1

## Faxioms Analysis

_As of 2026-09-18_

### Technical Outlook

As of September 18, 2026, Biocon's stock is trading at ₹385.0, with a daily technical stance indicating a bearish trend. The daily timeframe shows the price below key moving averages including the 20-day EMA (₹396.47), 50-day EMA (₹407.08), and the 200-day SMA (₹395.54), alongside a bearish Supertrend indicator at ₹404.62. This suggests short-term weakness. In contrast, the monthly timeframe presents a bullish picture, with the price above the 20-day EMA (₹383.15) and a bullish Supertrend at ₹276.45, indicating underlying strength over a longer period. The weekly timeframe shows mixed signals, with the price below its 20-day EMA (₹405.96) and 20-day SMA (₹415.86) but above a bullish Supertrend at ₹360.99. This divergence across timeframes suggests a consolidation or potential transition phase.

Nearest support is observed at ₹384.5, a level just below the current price, followed by ₹377.5. Resistance is noted around ₹388.31 and ₹389.0. The stock has experienced two recent market events in the past 30 days, both classified as positive attention events, including a moderate upward price and volume anomaly on September 18, 2026, with a volume ratio of 2.72. The stock's current drawdown stands at -13%, with annualized volatility at 29%. This indicates a moderate risk environment. Key conditions to watch include a sustained break above the ₹388.31 resistance level, which could signal a shift in the daily trend, and a close below the ₹384.5 support, which might confirm the bearish daily outlook.

- Current price on September 18, 2026: ₹385.0.
- Daily trend is bearish with price below key moving averages (e.g., 20-day EMA at ₹396.47).
- Monthly trend is bullish with price above the 20-day EMA (₹383.15).
- Nearest support level: ₹384.5; nearest resistance level: ₹388.31.
- Watch for a close above ₹388.31 to challenge the daily bearish trend, or a close below ₹384.5 to confirm it.

- Doji
- Bearish Engulfing Reversal
- Evening Star
- Harami

### News Context

The past seven days saw commentary on the broader Indian pharmaceutical sector's innovation challenges, with a specific mention of regulatory hurdles impacting early-stage drug trials. This context was highlighted in a report from The Economic Times on September 15, 2026, which noted that such complexities often lead Indian companies to conduct crucial first-in-human studies abroad, citing faster approval processes in countries like the US and Australia. The same day, a separate report featured insights from Kiran Mazumdar-Shaw, who predicted that technology is enabling younger leaders to emerge earlier in India, potentially transforming the economic landscape and driving global ambitions. This perspective was presented within the context of "ET Under 40 2026: How technology is creating younger leaders."

- On September 15, 2026, The Economic Times reported that India's regulatory environment for early-stage drug trials can be slow, causing companies to conduct initial human studies overseas.
- The same report on September 15, 2026, indicated that countries like the US and Australia offer quicker approval processes for clinical trials.
- Also on September 15, 2026, Kiran Mazumdar-Shaw was quoted in "ET Under 40 2026: How technology is creating younger leaders," suggesting technology is facilitating earlier leadership roles for younger Indians and influencing economic growth.

- ET Under 40 2026: How technology is creating younger leaders
- Agonisingly slow clinical trial is stopping Indian pharma become global innovator from supplier - The Economic Times

### What Changed

As of September 18, 2026, Biocon's stock price has seen a modest increase, trading at ₹385.0 compared to ₹380.0 previously. The available evidence does not indicate any new filings or news events that would explain this recent price movement. The company's profile on the NSE remains unchanged.

- Biocon's stock price was ₹385.0 on September 18, 2026.
- The previous stock price recorded was ₹380.0.
- No new filings or news were reported for Biocon as of September 18, 2026.

### Official Filings

Biocon Limited has announced several key developments. On August 25, 2026, its subsidiary Biocon Biologics Ltd. received marketing approval from Japan's Ministry of Health, Labour and Welfare for its pegfilgrastim biosimilar. This product will be promoted and sold in Japan by Sandoz K.K. Separately, on September 8, 2026, Biocon secured a 10-year supply contract for Pertuzumab in Brazil through a partnership with Bahiafarma and Bionovis under Brazil's Productive Development Partnership (PDP) program. This agreement grants exclusive access to approximately 70% of Brazil's Pertuzumab demand within the public healthcare market, with Biocon set to receive milestone payments and a share of revenues. The company also approved a final dividend of ₹0.50 per equity share for the fiscal year 2025-26, which was remitted to shareholders on or around September 9, 2026, following its approval at the Annual General Meeting on August 6, 2026.

- On August 25, 2026, Biocon Biologics received Japanese marketing approval for its pegfilgrastim biosimilar.
- On September 8, 2026, Biocon entered a 10-year supply contract for Pertuzumab in Brazil, securing access to a significant portion of the public healthcare market.
- A final dividend of ₹0.50 per equity share for FY 2025-26 was approved on August 6, 2026, and remitted to shareholders around September 9, 2026.

- Biocon Limited has informed the Exchange about Communication regarding remittance of final dividend for the FY 2025-26 |SUBJECT: General Updates
- Biocon Limited has informed the Exchange regarding a press release dated September 08, 2026, titled "Biocon Secures 10-Year Supply Contract for Pertuzumab in Brazil". |SUBJECT: Press Release
- Biocon Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- Biocon Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- Biocon Limited has informed the Exchange about "Communication regarding remittance of final dividend for the FY 2025-26" |SUBJECT: General Updates
- Biocon Limited has informed the Exchange regarding 'Company Statement'. |SUBJECT: Updates
- Biocon Limited has informed the Exchange regarding 'Company Statement'. |SUBJECT: Updates
- Biocon Limited has informed the Exchange about Transcript |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- Biocon Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- Biocon Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on August 06, 2026. Further, the company has informed the Exchange regarding voting results. |SUBJECT: Shareholders meeting

### Fundamentals

Biocon's recent operating performance shows a mixed trend across its reported quarters. Revenue from operations saw an increase from ₹4,173 crore in Q3 FY2025-26 to ₹4,516.60 crore in Q4 FY2025-26, before declining to ₹4,336 crore in Q1 FY2026-27. Expenses largely followed revenue, increasing from ₹4,064.70 crore in Q3 FY2025-26 to ₹4,241.20 crore in Q4 FY2025-26, and then slightly increasing further to ₹4,249.40 crore in Q1 FY2026-27. Profit Before Exceptional Items and Tax demonstrated a positive trajectory from Q3 FY2025-26 (₹225.60 crore) to Q4 FY2025-26 (₹327.90 crore), but then decreased to ₹141.10 crore in Q1 FY2026-27. Profit Before Tax also showed variability, moving from a loss of ₹67.80 crore in Q3 FY2025-26 to a profit of ₹247.50 crore in Q4 FY2025-26, and then ₹127.60 crore in Q1 FY2026-27. The net result, Profit Loss For Period, mirrored this pattern, with a loss of ₹51.80 crore in Q3 FY2025-26, a profit of ₹198.60 crore in Q4 FY2025-26, and ₹136.80 crore in Q1 FY2026-27. Tax expenses fluctuated, with a negative tax expense (a credit) in Q3 FY2025-26 and Q1 FY2026-27, and a positive expense in Q4 FY2025-26.

Key monitoring areas for Biocon would include the sustainability of revenue growth, the management of operating expenses to improve profitability, and the consistency of net profit generation across reporting periods. Understanding the drivers behind the fluctuations in Profit Before Tax and the impact of tax expenses will be crucial for assessing the company's earnings quality.

- Revenue from operations was ₹4,173 crore in Q3 FY2025-26, ₹4,516.60 crore in Q4 FY2025-26, and ₹4,336 crore in Q1 FY2026-27.
- Profit Loss For Period was -₹51.80 crore in Q3 FY2025-26, ₹198.60 crore in Q4 FY2025-26, and ₹136.80 crore in Q1 FY2026-27.
- Profit Before Tax showed a loss of ₹67.80 crore in Q3 FY2025-26, a profit of ₹247.50 crore in Q4 FY2025-26, and ₹127.60 crore in Q1 FY2026-27.
- Expenses were ₹4,064.70 crore in Q3 FY2025-26, ₹4,241.20 crore in Q4 FY2025-26, and ₹4,249.40 crore in Q1 FY2026-27.

### Bull Case

The company's monthly technical trend shows a bullish signal, with the Supertrend indicator at 276.45 and a bullish direction as of September 18, 2026. This is supported by a positive monthly EMA 20 at 383.15 and a higher monthly Plus DI (18.83) compared to the Minus DI (15.25). While the daily trend indicates a bearish Supertrend at 404.62, the weekly trend remains bullish with a Supertrend of 350.99. The company has also demonstrated positive returns over certain periods, including a 5.0% return over the last year and a 1.0% return over the last six months.

- As of September 18, 2026, the monthly Supertrend indicator is bullish at 276.45.
- The weekly Supertrend indicator is bullish at 350.99.
- The company's stock price has seen a 5.0% return over the past year.
- A 1.0% return was observed over the last six months.

- ET Under 40 2026: How technology is creating younger leaders
- Agonisingly slow clinical trial is stopping Indian pharma become global innovator from supplier - The Economic Times

### Bear Case

The company's stock is exhibiting a bearish trend on a daily basis, with the closing price of ₹385.0 below its 20-day Exponential Moving Average (EMA) of ₹396.47 and 50-day EMA of ₹407.08. The Supertrend indicator also signals a bearish direction. While the monthly trend shows a bullish Supertrend, the daily technical indicators suggest a cautious outlook. The stock has experienced a drawdown of -13% and a maximum drawdown of -25%, with annualized volatility at 29%. Recent returns show a decline over multiple periods, including -8% in the last month and -7% over the last 20 days, though it has seen a 5% return over the last year.

- Daily technical indicators, including the Supertrend, signal a bearish trend as of 2026-09-18.
- The closing price of ₹385.0 is below the 20-day EMA (₹396.47) and 50-day EMA (₹407.08).
- The stock has experienced a current drawdown of -13% and a maximum drawdown of -25%.
- Recent performance includes a -8% return in the last month and a -7% return over the last 20 days.

- ET Under 40 2026: How technology is creating younger leaders
- Agonisingly slow clinical trial is stopping Indian pharma become global innovator from supplier - The Economic Times

### FAQs

**What is the recent business development regarding Biocon's presence in Brazil?**

Biocon has secured a 10-year supply contract for Pertuzumab in Brazil through a partnership with Bahiafarma and Bionovis. This agreement, part of Brazil's Productive Development Partnership (PDP) program, grants the consortium exclusive access to approximately 70% of Brazil's public healthcare market for Pertuzumab. Biocon is expected to receive milestone payments and a share of revenues over the contract's duration, with plans for phased localization in Brazil.

**What was Biocon's dividend payout for the fiscal year 2025-26?**

Biocon Limited approved and remitted a final dividend of ₹0.50 per equity share for the fiscal year 2025-26. The dividend was approved at the 48th Annual General Meeting held on August 6, 2026, and was electronically remitted to shareholders based on the record date of July 3, 2026, after applicable tax deductions.

**What is the current technical trend for Biocon shares?**

As of September 18, 2026, Biocon's daily trend indicators suggest a bearish sentiment, with the Supertrend indicator at 404.62 and a 'bearish' direction. The 20-day Exponential Moving Average (EMA) is at 396.47, and the 50-day EMA is at 407.08, both above the current closing price of ₹385.0. However, the monthly trend shows a 'bullish' Supertrend at 276.45, indicating a different sentiment over a longer timeframe.

**What are the key support and resistance levels for Biocon shares?**

As of September 18, 2026, key technical levels for Biocon shares include immediate support near ₹384.5 (0.13% distance) and resistance around ₹388.31 (0.86% distance). Other identified resistance levels are at ₹389.0 and ₹396.0, while further support levels are noted at ₹377.5 and ₹373.0.

- ET Under 40 2026: How technology is creating younger leaders
- Agonisingly slow clinical trial is stopping Indian pharma become global innovator from supplier - The Economic Times
- Biocon Limited has informed the Exchange about Communication regarding remittance of final dividend for the FY 2025-26 |SUBJECT: General Updates
- Biocon Limited has informed the Exchange regarding a press release dated September 08, 2026, titled "Biocon Secures 10-Year Supply Contract for Pertuzumab in Brazil". |SUBJECT: Press Release
- Biocon Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- Biocon Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- Biocon Limited has informed the Exchange about "Communication regarding remittance of final dividend for the FY 2025-26" |SUBJECT: General Updates
## Technical analytics

- As of: 2026-09-18
- Daily trend: Moderate Downtrend
- Weekly trend: Weak Downtrend
- Pivot point: ₹377.5
- Risk regime: Price Risk Currently Contained

### Support levels
- 365.75
- 362.2619140625
- 346.45625

### Resistance levels
- 388.3109375
- 396.9
- 407.7585693359375

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +1.32% |
| return_10 | -4.23% |
| return_1m | -7.78% |
| return_1y | +4.51% |
| return_20 | -6.67% |
| return_3m | -6.97% |
| return_5 | -1.70% |
| return_6m | +0.63% |
| return_since_start | +4.39% |
| return_ytd | -0.71% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | contained_risk |
| label | Price risk currently contained |
| summary | Recent drawdown and price variability remain within the producer's contained-risk thresholds. |
| maximum_drawdown | -24.68% |
| annualized_volatility | +29.32% |

## Quarterly financials

- Latest complete quarter: fy27_q1

# Revenue Declined Sequentially While Expenses Held Steady, Squeezing Profitability

Biocon Ltd.’s results for the quarter ended June 30, 2026 (FY2026-27 Q1) showed revenue falling from the prior quarter while total expenses remained nearly flat, narrowing the gap between income and costs. Compared with the same quarter a year earlier, both revenue and profit were higher. A tax credit and falling finance costs helped cushion the bottom line, though a sharp drop in inter-segment revenue and a divergence between net profit and earnings per share marked notable shifts in the quarter’s financial results.

## Revenue and Expense Trends

Revenue from operations was ₹4,336 crore, down 4% from ₹4,516.6 crore in the March quarter, but up 10% from ₹3,941.9 crore in the same quarter last year. The sequential decline followed a March quarter that had been the highest revenue in the past five quarters. Total expenses were ₹4,249.4 crore, essentially unchanged from ₹4,241.2 crore in the prior quarter (up 0.2%), and 8.3% higher than the year-ago quarter. The combination of lower revenue and stable expenses narrowed the gap between revenue and expenses to ₹86.6 crore from ₹275.4 crore in the prior quarter.

## Profitability Compression

Profit before exceptional items and tax fell to ₹141.1 crore from ₹327.9 crore in the prior quarter, a decline of 57%. The year-over-year comparison remained positive at ₹141.1 crore versus ₹96.9 crore, an increase of 46%. After accounting for exceptional items (a net charge of ₹13.5 crore), profit before tax was ₹127.6 crore, down 48% sequentially but up 32% from a year ago. Net profit for the period was ₹136.8 crore, down 31% from ₹198.6 crore in the prior quarter, but up 53% from ₹89.2 crore in the year-ago quarter. The sequential decline in net profit was less severe than the drop in pre-exceptional profit because the tax line turned into a ₹9.2 crore credit in the current quarter, compared to a ₹48.9 crore expense in the prior quarter, providing a partial offset.

## Finance Costs and Inter-Segment Revenue

Finance costs were ₹213.2 crore, down 8% from the prior quarter and 23% lower than the year-ago quarter. This follows a pattern of declining finance costs over the past several quarters. Inter-segment revenue fell sharply to ₹15.3 crore from ₹122.2 crore in the prior quarter, an 87% drop, and was also significantly below the ₹86.9 crore recorded in the same quarter last year.

## Other Comprehensive Income and Earnings Per Share

Other comprehensive income was ₹788.8 crore, down 19% from ₹974.3 crore in the prior quarter. This item has shown significant volatility in recent periods, ranging from a loss of ₹205.5 crore in the first quarter of last year to gains exceeding ₹970 crore in subsequent quarters. Basic earnings per share from continuing operations was ₹0.87, up from ₹0.79 in the prior quarter and ₹0.26 a year ago. This sequential increase in per-share earnings occurred despite a decline in total net profit for the period, indicating a divergence between the two measures.

## Key Takeaway

Biocon’s first quarter was characterized by a sequential revenue decline met with steady expenses, which compressed profitability relative to the prior quarter. Year-over-year growth in revenue and net profit remained solid. Finance costs continued their downward trajectory, and a reversal to a tax credit helped support the bottom line. The substantial drop in inter-segment revenue and the divergence between total net profit and earnings per share were the other defining features of the quarter.

### Ratios

## Official filings

- 2026-09-09 — Generic Announcement: Biocon Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/BIOCON_09092026135825_SE_Intimation.pdf)
- 2026-09-08 — Press Release: Biocon Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/BIOCON_08092026083042_Pressrelease08092026.pdf)
- 2026-09-08 — Generic Announcement: Biocon Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/BIOCON_08092026155308_Investor_Roadshow_11_Sep_2026.pdf)
- 2026-08-31 — Generic Announcement: Biocon Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/BIOCON_31082026180408_Nuvama_Credit_Conference_04_Sep_2026.pdf)
- 2026-08-28 — Generic Announcement: Biocon Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/BIOCON_28082026205918_SE_Intimation.pdf)
- 2026-08-25 — Generic Announcement: Biocon Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/BIOCON_25082026082811_SE25082026.pdf)
- 2026-08-18 — Generic Announcement: Biocon Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/BIOCON_18082026083950_CoStatement18062026.pdf)
- 2026-08-11 — Earnings Transcript: Biocon Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/BIOCON_11082026200302_Cover_Letter_Transcript_Earnings_Call.pdf)
- 2026-08-11 — Generic Announcement: Biocon Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/BIOCON_11082026200613_Motilal_Oswal_Conference_17_August_2026.pdf)
- 2026-08-08 — Management Change: Biocon Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/BIOCON_08082026215336_Voting_Results_and_Scrutinizer_Report.pdf)
- 2026-08-07 — Management Change: Biocon Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_2181_WebXMLFile_20260807_200358677.xml)
- 2026-08-07 — Generic Announcement: Biocon Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/BIOCON_07082026204633_Emkay_Conference_12_August_2026.pdf)
- 2026-08-07 — Management Change: Biocon Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_2181_WebXMLFile_20260807_193358209.xml)
- 2026-08-07 — Management Change: Biocon Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_2181_WebXMLFile_20260807_195429682.xml)
- 2026-08-07 — Generic Announcement: Biocon Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/BIOCON_07082026202418_NewspaperAd_Financials.pdf)
- 2026-08-07 — Generic Announcement: Biocon Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/BIOCON_07082026204337_Emkay_Conference_12_August_2026.pdf)
- 2026-08-06 — Generic Announcement: Biocon Limited announced changes at its 48th Annual General Meeting on August 6, 2026. Mr. Eric Vivek Mazumdar was re-appointed as a Director liable to retire by rotation. B S R & Co. LLP retired as Statutory Auditors due to term expiry, and S.R. Batliboi & Associates LLP was appointed as the new Statutory Auditors for a five-year term concluding at the 53rd AGM in 2031. Mr. Nicholas Robert Haggar retired as an Independent Director upon completion of his term. — [Official attachment](https://nsearchives.nseindia.com/corporate/BIOCON_06082026210357_SEs_Intimation_Director.pdf)
- 2026-08-06 — Generic Announcement: Biocon Limited held its 48th Annual General Meeting on August 6, 2026, via video conference. Key discussions included the adoption of audited financial statements for the year ended March 31, 2026, the declaration of a final dividend of ₹0.50 per equity share, the re-appointment of Eric Vivek Mazumdar as Director, and the appointment of S.R. Batliboi & Associates LLP as Statutory Auditors. Special business involved approving the Biocon Unity Long Term Incentive Plan 2026 and related stock unit plans for employees and subsidiaries, authorizing financial assistance for its implementation, and ratifying the remuneration of Cost Auditors for 2026-27. The meeting also noted the completion of tenure for certain directors and the statutory auditors. — [Official attachment](https://nsearchives.nseindia.com/corporate/BIOCON_06082026204223_Biocon_AGM_Proceedings_and_Chairperson_Speech.pdf)
- 2026-08-06 — Management Change: Biocon Limited announced the resignation of B S R & Co. LLP as the statutory auditors of its material subsidiary, Biocon Biologics Limited (BBL), effective August 6, 2026. The resignation is to align BBL's auditors with Biocon Limited's auditors due to the mandatory rotation of B S R & Co. LLP as the holding company's auditor. B S R & Co. LLP had been appointed as BBL's statutory auditors on July 26, 2022, and their term was scheduled to conclude at the AGM following the financial year ending March 31, 2027. — [Official attachment](https://nsearchives.nseindia.com/corporate/BIOCON_06082026232143_SE_Intimation-Resignation_of_statutory_auditors_of_Subsidiaries.pdf)
- 2026-08-06 — Generic Announcement: Biocon Limited has made available the audio and video recording of its Q1 FY27 Earnings Call held on August 06, 2026. The recording can be accessed via a provided link and is also available on the company's website. This disclosure is made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. — [Official attachment](https://nsearchives.nseindia.com/corporate/BIOCON_06082026183935_Earning_Calls_outcome05082026.pdf)
- 2026-08-06 — Management Change: Biocon Limited announced changes at its 48th Annual General Meeting on August 6, 2026. Mr. Eric Vivek Mazumdar was re-appointed as a Director liable to retire by rotation. B S R & Co. LLP retired as Statutory Auditors due to term expiry, and S.R. Batliboi & Associates LLP was appointed as the new Statutory Auditors for a five-year term concluding at the 53rd AGM in 2031. Mr. Nicholas Robert Haggar retired as an Independent Director upon completion of his term. — [Official attachment](https://nsearchives.nseindia.com/corporate/BIOCON_06082026205827_SEs_Intimation_Director.pdf)
- 2026-08-06 — Earnings Presentation: Biocon Limited announced its Q1 FY27 earnings call presentation on August 6, 2026. The company highlighted growth in its Biosimilars segment, driven by North America, with EBITDA up 10% year-over-year. The Generics segment saw revenues increase 21% year-over-year, with generic liraglutide being a key driver. The Services segment's performance was impacted by lower offtake from a key biologics client and forex hedge losses. Biocon anticipates FY27 to be a transition year, with performance improving in the second half. — [Official attachment](https://nsearchives.nseindia.com/corporate/BIOCON_06082026072054_IR_PPT_Cover_Letter.pdf)
- 2026-08-06 — Generic Announcement: Biocon Limited announced changes at its 48th Annual General Meeting on August 6, 2026. Mr. Eric Vivek Mazumdar was re-appointed as a Director liable to retire by rotation. B S R & Co. LLP retired as Statutory Auditors due to term expiry, and S.R. Batliboi & Associates LLP was appointed as the new Statutory Auditors for a five-year term concluding at the 53rd AGM in 2031. Mr. Nicholas Robert Haggar retired as an Independent Director upon completion of his term. — [Official attachment](https://nsearchives.nseindia.com/corporate/BIOCON_06082026210732_SEs_Intimation_Director.pdf)
- 2026-08-05 — Generic Announcement: Biocon Limited has submitted its Monitoring Agency Report for the quarter ended June 30, 2026, concerning the utilization of proceeds from its Qualified Institutions Placement (QIP). India Ratings & Research Private Limited, the monitoring agency, reported no deviation from the stated objects of the QIP. The QIP, which raised INR 41,500.00 Million, was for the acquisition of shares in Biocon Biologics Limited from Mylan Inc., repayment of debt, and general corporate purposes. The Audit Committee and Board of Directors reviewed and noted the report on August 5, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/BIOCON_05082026170816_SE_Intimation_-_Monitoring_Agency.pdf)
- 2026-08-05 — Press Release: Biocon Limited reported its un-audited consolidated financial results for the quarter ended June 30, 2026. Total income was Rs 4,391 crore, a 9% increase year-over-year. EBITDA stood at Rs 902 crore, with a 21% margin. Net profit was Rs 141 crore. Biopharma revenue increased by 17% year-over-year, driven by biosimilar and generic product launches. — [Official attachment](https://nsearchives.nseindia.com/corporate/BIOCON_05082026170201_PressRelease05082026.pdf)

## News and market events

- 2026-09-18 — NEWS.WEBINDIA123.COM: **Indias pharma sector poised to move from manufacturing strength to global innovation leadership** — Dr M Srinivas, Member (Health), NITI Aayog, emphasised the importance of academia-Industry partnership while addressing the 8th CII Pharma and Lifesciences Summit, themed Future of Pharma: Patient-Centric, Equity-Driven, and Innovation-Led, held on Friday in New Delhi in partnership with the Department of Pharmaceuticals. — [Source](https://news.webindia123.com/news/articles/india/20260918/4500375.html)
- 2026-09-15 — Economic Times: **ET Under 40 2026: How technology is creating younger leaders** — The rise of technology is paving the way for younger Indians to step into leadership roles much earlier. Kiran Mazumdar-Shaw predicts that the notion of age-based distinctions might soon vanish. Driven by innovation, these young leaders are daring to take risks and develop groundbreaking business strategies. This fresh wave of leadership promises to significantly influence India's economic landscape, forging a path towards global ambitions fueled by technology. — [Source](https://economictimes.indiatimes.com/news/company/corporate-trends/et-under-40-2026-how-technology-is-creating-younger-leaders/articleshow/134271381.cms)
- 2026-09-15 — Economic Times: **Agonisingly slow clinical trial is stopping Indian pharma become global innovator from supplier - The Economic Times** — India's regulatory hurdles slow down early-stage drug trials significantly. This complexity causes Indian companies to conduct crucial first-in-human studies abroad. Other nations like the US and Australia offer faster approval processes for trials. China now leads in novel medicine development due to its streamlined regulatory environment. Reforming India's system can unlock its potential in novel drug innovation. — [Source](https://economictimes.indiatimes.com/opinion/et-commentary/agonisingly-slow-clinical-trial-is-stopping-indian-pharma-become-global-innovator-from-supplier/articleshow/134270502.cms)
- 2026-09-09 — MONEYCONTROL: **Biocon block deals: True North affiliate offloads Rs 638 crore worth shares; Citi, WhiteOak, SBI MF, Kotak Mahindra AMC among buyers** — Biocon block deals,Biocon stock price,ICICI Prudential Mutual Fund,Activ Pine LLP — [Source](https://www.moneycontrol.com/news/business/markets/biocon-block-deals-true-north-affiliate-offloads-rs-638-crore-worth-shares-citi-whiteoak-sbi-mf-kotak-mahindra-amc-among-buyers-14026425.html)
- 2026-09-09 — CNBC-TV18: **Biocon shares gain nearly 3% after equity worth ₹630 crore changes hands in block deal** — As of June 30, the total shareholding of Active Pine was 1.08% in Biocon, as per data available on the stock exchanges. With the entire equity having changed hands, Active Pine would have completely exited the stock. — [Source](https://www.cnbctv18.com/market/biocon-share-price-block-deal-value-size-active-pine-exit-shareholding-returns-19987154.htm)
- 2026-09-09 — BUSINESSTODAY: **Top stocks in news: Biocon, TCS, Bank of Baroda, NLC India, Innovision, GE Shipping, Moschip, Raymond** — Stocks in news, Stocks in buzz, Stocks to buy, Stocks to watch, Biocon, TCS, Bank of Baroda, NLC India, Innovision, GE Shipping, Moschip, Raymond, Berger Paints, Tata Consultancy Services, Enviro Infra Engineers, Moschip Technologies, Great Eastern Shipping Company, Laxmi Organic Industries, Fermenta Biotech — [Source](https://www.businesstoday.in/markets/stocks/story/top-stocks-in-news-biocon-tcs-bank-of-baroda-nlc-india-innovision-ge-shipping-moschip-raymond-554118-2026-09-09)
- 2026-09-09 — Economic Times: **Stocks in news: Biocon, Bank of Baroda, TCS, Sanofi India and Tata Capital** — Indian equity markets hit a seven-week low on Tuesday, primarily due to escalating crude oil prices and geopolitical instability that swayed investor morale. Notably, Bank of Baroda announced plans to divest its interest in the NSE, while TCS secured a major contract. Other companies such as Sanofi India and Piramal Finance also shared pivotal developments, highlighting a mixed bag of corporate activity. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/stocks-in-news-biocon-bank-of-baroda-tcs-sanofi-india-and-tata-capital/articleshow/133910314.cms)
- 2026-09-08 — CNBC-TV18: **Biocon Block Deal: Active Pine likely to sell 1.66 crore shares at ₹385 per share** — Shares of Biocon Ltd ended at ₹392.55, down by ₹0.95, or 0.24%, on the BSE. — [Source](https://www.cnbctv18.com/market/stocks/biocon-block-deal-active-pine-likely-to-sell-1-66-crore-shares-at-%25e2%2582%25b9385-per-share-19986870.htm)
- 2026-09-08 — CNBC-TV18: **Biocon sees double-digit biosimilars growth continuing, targets mid-20% margins** — Biocon expects its biosimilars business to maintain double-digit revenue growth as it expands its portfolio, with management saying the path to $1 billion in revenue is a question of when, not if. The company also plans to cut leverage below 2x and could use its Malaysia facility to manufacture peptides and GLP-1 products. — [Source](https://www.cnbctv18.com/business/companies/biocon-sees-usd-1-billion-biosimilars-target-in-sight-eyes-glp-1-growth-from-malaysia-19986633.htm)
- 2026-09-08 — Economic Times: **Biocon shares rise 2% on 10-year Pertuzumab supply deal for breast cancer therapy in Brazil** — Biocon shares rose after the company secured a 10-year Pertuzumab supply contract in Brazil. The consortium with Bahiafarma and Bionovis received full allocation under the countrys PDP programme, providing access to around 70% of public-sector demand. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/biocon-shares-rise-2-on-10-year-pertuzumab-supply-deal-for-breast-cancer-therapy-in-brazil/articleshow/133910110.cms)
- 2026-09-08 — MONEYCONTROL: **Biocon shares rise 1.4% after 10-year Pertuzumab partnership in Brazil** — Bahiafarma, Bionovis, Pertuzumab, Biocon, Brazil, Biocon stocks today, Biocon share price, Biocon, BSE, NSE, Stocks — [Source](https://www.moneycontrol.com/news/business/stocks/biocon-shares-rise-1-4-after-10-year-pertuzumab-partnership-in-brazil-14024990.html)
- 2026-08-18 — The Hindu: **Sensex today | Stock Market Live: Sensex down 250 pts in early trade, Nifty below 24,250; Infosys, IndiGo top losers** — Sensex, Nifty, Share Prices LIVE: Indian stocks open on a negative note on Tuesday amid mixed global cues — [Source](https://www.thehindubusinessline.com/markets/stock-market-live-sensex-nifty50-today-live-updates-today-18th-august-2026/article71358725.ece)
- 2026-08-10 — Economic Times: **Independence Day 2026: India, which once couldn't make smallpox vaccine, has now crossed a pharma milestone the world can't ignore** — 2026 Independence Day: India's pharmaceutical industry marks a historic milestone with a new drug approval. This achievement reflects decades of growth from importing medicines to global leadership. The nation now supplies a significant portion of the world's generic medicines and vaccines. The Covid-19 pandemic further showcased the industry's manufacturing capabilities globally. Government initiatives now aim to foster innovation and high-value biopharmaceutical production. — [Source](https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/independence-day-2026-india-pharma-journey-covaxin-made-in-india-drug-discovery-zaynich-wockhardt-ipa-indian-medicine-vaccine/articleshow/133003617.cms)
- 2026-08-07 — The Hindu: **Q1 Results Today Live: SBI, Titan, Hindalco, Hitachi Energy, PFC, Godrej Consumer, Oil India, NLC, Kaynes Tech, Ramco Cements, Afcons Infra, Lemon Tree, Cello to announce Q1 results, LIC, Hero Motocorp, Britannia, Siemens Energy, Muthoot Microfin shares gain, Trent, Premier Energies decline after Q1** — Q1 Results Today, 07th August 2026 Live Updates: Follow Q1FY27 live updates from businessline — [Source](https://www.thehindubusinessline.com/markets/q1-results-today-live-updates-sbi-titan-hindalco-power-finance-corporation-godrej-consumer-oil-india-nlc-kaynes-tech-ramco-cements-afcons-infra-lemon-tree-cello-hitachi-lic-trent-results-07-august-202/article71313123.ece)
- 2026-08-07 — CNBC-TV18: **Q1 Results LIVE Updates: Siemens Energy shares rise over 10%, Samvardhana Motherson up 6%** — Q1 Results LIVE Updates: Three Nifty 50 companies, SBI, Hindalco and Titan, as well as Kaynes Tech, BEML, Aarti Pharmalabs, Azad Engineering, Godrej Consumer, JK Tyre, Jubilant Pharmova, Maharashtra Seamless, Lemon Tree Hotels, Oil India, PFC, ABB India, Poly Medicure, Ramco Cements, Prism Johnson, Raymond, Raymond Realty, Ratnamani Metals & Tubes, among other companies are reporting their earnings today. Earnings reactions come from LIC, Hero MotoCorp, PG Electroplast, Britannia, Sonata Software and other companies. Watch this space for all the LIVE result updates for Q1. — [Source](https://www.cnbctv18.com/market/q1-results-live-updates-sbi-hindalco-titan-lic-pg-electroplast-hero-britannia-pfc-abb-beml-kaynes-fortis-azad-engg-share-price-liveblog-19963817.htm)
- 2026-08-07 — The Hindu: **Sensex today | Stock Market Live: Sensex down 250 pts, Nifty touches 24,600 on rising oil prices; IT stocks lead Nifty gains as financials bleed** — Sensex, Nifty, Share Prices Live: Sensex traded 344.86 pts or 0.44% lower at 78,609.90 at 9.17 am after opening at  78,516.08 from the previous close of 78,954.76. Nifty 50 declined 50.60 pts or 0.21% to 24,585.40. — [Source](https://www.thehindubusinessline.com/markets/sensex-nifty50-today-stock-market-live-updates-7th-august-2026/article71314561.ece)
- 2026-08-07 — CNBC-TV18: **Sensex Today | Stock Market Live Updates: GIFT Nifty 90 pts lower; Jefferies raises target for Premier Eng** — Sensex Today | Stock Market Live Updates: The index holding on to 24,500 levels on the downside is something that the bulls will be pleased with as analysts believe it is forming a base for a move, first towards 24,800, and eventually to record levels. Crude oil prices though, have staged a minor rebound overnight with brent returning to above $80 a barrel. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-cas-tata-hero-pgel-lic-sci-sbi-ncc-premier-crompton-midcaps-share-price-liveblog-19963799.htm)
- 2026-08-06 — The Hindu: **Q1 Results Today Live: Trent, Hero MotoCorp, Lupin, Britannia, Siemens Energy, LIC, BOSCH, Kirloskar Oil Engines, Aegis Logistics, Premier Energies, Emcure Pharma to announce Q1 results, Biocon, Berger Paints, Neuland Lab, ArisInfra gain, Aurobindo Pharma, Aster DM, Whirlpool, PB Fintech, Power Grid, Godrej Agrovet in red after Q1** — Q1 Results Today, 06th August 2026 Live Updates: Follow Q1FY27 live updates frmo businessline — [Source](https://www.thehindubusinessline.com/markets/q1-results-today-live-updates-trent-britannia-siemens-energy-hero-motocorp-lupin-lic-kirloskar-oil-engines-bosch-aegis-logistics-premier-energies-emcure-pharma-blue-star-results-06-august-2026/article71312019.ece)
- 2026-08-06 — MONEYCONTROL: **Price Action | PNC Infratech falls 4% on NHAI show-cause notice; Swan Defence hits 52-week high on order win** — Buzzing Stocks — [Source](https://www.moneycontrol.com/news/business/markets/price-action-pnc-infratech-falls-4-on-nhai-show-cause-notice-swan-defence-hits-52-week-high-on-order-win-13995971.html)
- 2026-08-06 — CNBC-TV18: **Q1 Results LIVE Updates: Neuland Laboratories jumps 11%, Aster DM up 3% on earnings** — Q1 Results LIVE Updates; Trent, Britannia, Lupin, Samvardhana Motherson, Apollo Tyres, Blue Star, Premier Energies, HCC, NCC, PG Electroplast, Emcure Pharma, Firstsource Solutions are some of the many companies that will be reporting their results during the course of Thursday's trading session on Dalal Street. Result reactions today come from PB Fintech, Aurobindo Pharma, Cummins India, GE Vernova T&D, ION Exchange and many others. Watch this space for all the LIVE Q1 result updates, management and brokerage commentary along with stock moves. — [Source](https://www.cnbctv18.com/market/q1-results-live-updates-cummins-ge-vernova-td-pb-fintech-trent-britannia-hero-lupin-samil-pgel-apollo-tyres-sci-ncc-hcc-premier-energies-share-price-liveblog-19962840.htm)

## Business profile

**Strategic vision:** Global biopharmaceutical company focused on affordable innovation.

### Business segments
- **Generics:** The Generics segment is dedicated to delivering quality, cost-saving, and life-saving solutions to patients, partners, and healthcare systems globally. Biocon's Generics portfolio includes Active Pharmaceutical Ingredients (API) and Generic Formulations.
- **Biosimilars:** Biocon's Biosimilars business operates primarily through its subsidiary, Biocon Biologics. This segment is focused on making potentially life-saving drugs affordable and accessible, thereby reducing health inequality and enabling patients to live prolonged, better quality lives.
- **Research Services:** Biocon has a historical relationship with Syngene International Limited, a contract research and manufacturing company providing drug discovery and development services. Syngene operates globally, including in India, the United States, and Europe.
- **Novel Biologics:** The Novel Biologics segment is dedicated to enabling cutting-edge therapies, particularly in oncology and immunology. This portfolio comprises both in-house developed and partnered products.

### Competitive strengths
- Fully integrated drug value chain operations
- Focus on affordable innovation for unmet medical needs
- Strengths in manufacturing operations, research and development capabilities, and commitment to quality and compliance in Generics
- Extensive pipeline of novel biologics in oncology and immunology

## Related stocks

- [ABBOTINDIA (Healthcare)](https://faxioms.com/stocks/abbotindia) — +5.25%
- [ACUTAAS (Healthcare)](https://faxioms.com/stocks/acutaas) — +3.78%
- [AJANTPHARM (Healthcare)](https://faxioms.com/stocks/ajantpharm) — +1.80%
- [ALKEM (Healthcare)](https://faxioms.com/stocks/alkem) — +2.21%
- [ANTHEM (Healthcare)](https://faxioms.com/stocks/anthem) — +0.12%

## Freshness and sources

- Data as of: 2026-09-18
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/biocon
Markdown representation: https://faxioms.com/stocks/biocon?render=md